ZypAdhera ® (olanzapine pamoate monohydrate)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: ZypAdhera Summary of Product Characteristics (SmPC)

ZypAdhera® (olanzapine pamoate): Use of other solvent than that supplied in the kit

Olanzapine pamoate must be suspended using only the diluent supplied in the kit. Other diluents should not be used, because they do not maintain the necessary wetting and re-suspension properties.

Further Information

Do not use olanzapine pamoate that has been suspended using other solvent than the solvent supplied in the kit.1

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: February 13, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question